Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,29880085,bioavailability,"The total clearance (CL/F) of oral and intravenous given IMA was increased by 1.41 and 1.32-fold, and the bioavailability was greatly decreased about 30.43% and 24.40% respectively.",Effects of aprepitant on the pharmacokinetics of imatinib and its main metabolite in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29880085/),%,30.43,17060,DB00673,Aprepitant
,29880085,bioavailability,"The total clearance (CL/F) of oral and intravenous given IMA was increased by 1.41 and 1.32-fold, and the bioavailability was greatly decreased about 30.43% and 24.40% respectively.",Effects of aprepitant on the pharmacokinetics of imatinib and its main metabolite in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29880085/),%,24.40,17061,DB00673,Aprepitant
,18317761,CL/F,"Typical population estimates of CL/F, apparent distribution volume (V(d)/F), absorption constant (K(a)) and absorption lag time were 1.54 L/h, 72.1 L, 0.893/h and 0.295 h, respectively.",Population pharmacokinetics of aprepitant and dexamethasone in the prevention of chemotherapy-induced nausea and vomiting. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18317761/),[l] / [h],1.54,17542,DB00673,Aprepitant
,18317761,apparent distribution volume (V(d)/F),"Typical population estimates of CL/F, apparent distribution volume (V(d)/F), absorption constant (K(a)) and absorption lag time were 1.54 L/h, 72.1 L, 0.893/h and 0.295 h, respectively.",Population pharmacokinetics of aprepitant and dexamethasone in the prevention of chemotherapy-induced nausea and vomiting. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18317761/),l,72.1,17543,DB00673,Aprepitant
,18317761,apparent distribution volume (V(d)/F),"Typical population estimates of CL/F, apparent distribution volume (V(d)/F), absorption constant (K(a)) and absorption lag time were 1.54 L/h, 72.1 L, 0.893/h and 0.295 h, respectively.",Population pharmacokinetics of aprepitant and dexamethasone in the prevention of chemotherapy-induced nausea and vomiting. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18317761/),1/[h],0.893,17544,DB00673,Aprepitant
,18317761,absorption constant (K(a)),"Typical population estimates of CL/F, apparent distribution volume (V(d)/F), absorption constant (K(a)) and absorption lag time were 1.54 L/h, 72.1 L, 0.893/h and 0.295 h, respectively.",Population pharmacokinetics of aprepitant and dexamethasone in the prevention of chemotherapy-induced nausea and vomiting. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18317761/),l,72.1,17545,DB00673,Aprepitant
,18317761,absorption constant (K(a)),"Typical population estimates of CL/F, apparent distribution volume (V(d)/F), absorption constant (K(a)) and absorption lag time were 1.54 L/h, 72.1 L, 0.893/h and 0.295 h, respectively.",Population pharmacokinetics of aprepitant and dexamethasone in the prevention of chemotherapy-induced nausea and vomiting. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18317761/),1/[h],0.893,17546,DB00673,Aprepitant
,18317761,absorption lag time,"Typical population estimates of CL/F, apparent distribution volume (V(d)/F), absorption constant (K(a)) and absorption lag time were 1.54 L/h, 72.1 L, 0.893/h and 0.295 h, respectively.",Population pharmacokinetics of aprepitant and dexamethasone in the prevention of chemotherapy-induced nausea and vomiting. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18317761/),h,0.295,17547,DB00673,Aprepitant
,17051369,plasma AUC ratios,"The mean plasma concentration profile of vinorelbine administered with aprepitant was identical to that following vinorelbine administered alone, with geometric mean vinorelbine plasma AUC ratios of treatment B day 1/treatment A day 1 and of treatment B day 8/treatment A day of 1.01 (0.93, 1.10) and 1.00 (0.92, 1.08), respectively.",Aprepitant when added to a standard antiemetic regimen consisting of ondansetron and dexamethasone does not affect vinorelbine pharmacokinetics in cancer patients. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17051369/),,1.01,25530,DB00673,Aprepitant
,17051369,plasma AUC ratios,"The mean plasma concentration profile of vinorelbine administered with aprepitant was identical to that following vinorelbine administered alone, with geometric mean vinorelbine plasma AUC ratios of treatment B day 1/treatment A day 1 and of treatment B day 8/treatment A day of 1.01 (0.93, 1.10) and 1.00 (0.92, 1.08), respectively.",Aprepitant when added to a standard antiemetic regimen consisting of ondansetron and dexamethasone does not affect vinorelbine pharmacokinetics in cancer patients. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17051369/),,1.00,25531,DB00673,Aprepitant
,15838656,AUC,"Six patients were enrolled in a protocol that employed a 4-day course of CTC high-dose chemotherapy with cyclophosphamide (1,500 mg/m2/day), thiotepa (120 mg/m2/day) and carboplatin (AUC 5 mg min/ml/day).",Aprepitant inhibits cyclophosphamide bioactivation and thiotepa metabolism. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15838656/),[mg·min] / [d·ml],5,42743,DB00673,Aprepitant
,15838656,IC50,"In human liver microsomes, the 50% inhibitory concentrations (IC50) of aprepitant for inhibition of cyclophosphamide (IC50=1.3 microg/ml) and thiotepa (IC50=0.27 microg/ml) metabolism were within the therapeutic range.",Aprepitant inhibits cyclophosphamide bioactivation and thiotepa metabolism. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15838656/),[μg] / [ml],1.3,42744,DB00673,Aprepitant
,15838656,IC50,"In human liver microsomes, the 50% inhibitory concentrations (IC50) of aprepitant for inhibition of cyclophosphamide (IC50=1.3 microg/ml) and thiotepa (IC50=0.27 microg/ml) metabolism were within the therapeutic range.",Aprepitant inhibits cyclophosphamide bioactivation and thiotepa metabolism. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15838656/),[μg] / [ml],0.27,42745,DB00673,Aprepitant
,18985740,Complete response (CR) rates,Complete response (CR) rates were 35.7% for aprepitant triple therapy versus 5.6% for the control group.,"Aprepitant in adolescent patients for prevention of chemotherapy-induced nausea and vomiting: a randomized, double-blind, placebo-controlled study of efficacy and tolerability. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18985740/),%,35.7,50239,DB00673,Aprepitant
,18985740,Complete response (CR) rates,Complete response (CR) rates were 35.7% for aprepitant triple therapy versus 5.6% for the control group.,"Aprepitant in adolescent patients for prevention of chemotherapy-induced nausea and vomiting: a randomized, double-blind, placebo-controlled study of efficacy and tolerability. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18985740/),%,5.6,50240,DB00673,Aprepitant
,16490805,bioavailabilities,"The mean (95% confidence interval [CI]) bioavailabilities of 125-mg and 80-mg final market composition (FMC) capsules, as assessed by simultaneous administration of stable isotope-labeled intravenous (i.v.) aprepitant (2 mg) and FMC capsules, were 0.59 (0.53, 0.65) and 0.67 (0.62, 0.73), respectively.",Pharmacokinetics of aprepitant after single and multiple oral doses in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16490805/),,0.59,52252,DB00673,Aprepitant
,16490805,bioavailabilities,"The mean (95% confidence interval [CI]) bioavailabilities of 125-mg and 80-mg final market composition (FMC) capsules, as assessed by simultaneous administration of stable isotope-labeled intravenous (i.v.) aprepitant (2 mg) and FMC capsules, were 0.59 (0.53, 0.65) and 0.67 (0.62, 0.73), respectively.",Pharmacokinetics of aprepitant after single and multiple oral doses in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16490805/),,0.67,52253,DB00673,Aprepitant
,16490805,area under the plasma concentration time curve (AUC) ratios,"The geometric mean (90% CI) area under the plasma concentration time curve (AUC) ratios (fed/fasted) were 1.2 (1.10, 1.30) and 1.09 (1.00, 1.18) for the 125-mg and 80-mg capsule, respectively, demonstrating that aprepitant can be administered independently of food.",Pharmacokinetics of aprepitant after single and multiple oral doses in healthy volunteers. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16490805/),,1.2,52254,DB00673,Aprepitant
,16490805,area under the plasma concentration time curve (AUC) ratios,"The geometric mean (90% CI) area under the plasma concentration time curve (AUC) ratios (fed/fasted) were 1.2 (1.10, 1.30) and 1.09 (1.00, 1.18) for the 125-mg and 80-mg capsule, respectively, demonstrating that aprepitant can be administered independently of food.",Pharmacokinetics of aprepitant after single and multiple oral doses in healthy volunteers. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16490805/),,1.09,52255,DB00673,Aprepitant
,26779916,Maximum tolerated dose,Maximum tolerated dose was 400 mg of pazopanib and 75 mg/m(2) of cisplatin.,Pharmacokinetic interaction between pazopanib and cisplatin regimen. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26779916/),mg,400,56757,DB00673,Aprepitant
,26779916,Maximum tolerated dose,Maximum tolerated dose was 400 mg of pazopanib and 75 mg/m(2) of cisplatin.,Pharmacokinetic interaction between pazopanib and cisplatin regimen. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26779916/),mg,75,56758,DB00673,Aprepitant
,26779916,clearance,Mean (CV % for inter-individual variability) cisplatin clearance was 10.3 L/h (33.2 %) and appeared not to be influenced by pazopanib.,Pharmacokinetic interaction between pazopanib and cisplatin regimen. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26779916/),[l] / [h],10.3,56759,DB00673,Aprepitant
,26779916,clearance,"Mean (CV %) of oral pazopanib clearance was 0.66 L/h (55 %) at Day 0 (before cisplatin administration), 24.8 % lower at Day 1 and 32.9 % lower at Day 2.",Pharmacokinetic interaction between pazopanib and cisplatin regimen. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26779916/),[l] / [h],0.66,56760,DB00673,Aprepitant
longer,23808489,human,"However, compound 2 is predicted, based on data in preclinical species, to have a human half-life longer than 40 h and likely to have drug-drug-interactions (DDI), as 2 is a victim of CYP3A4 inhibition caused by its exclusive clearance pathway via CYP3A4 oxidation in humans.","2-[(3aR,4R,5S,7aS)-5-{(1S)-1-[3,5-bis(trifluoromethyl)phenyl]-2-hydroxyethoxy}-4-(2-methylphenyl)octahydro-2H-isoindol-2-yl]-1,3-oxazol-4(5H)-one: a potent human NK1 receptor antagonist with multiple clearance pathways. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23808489/),h,40,59709,DB00673,Aprepitant
longer,23808489,half-life,"However, compound 2 is predicted, based on data in preclinical species, to have a human half-life longer than 40 h and likely to have drug-drug-interactions (DDI), as 2 is a victim of CYP3A4 inhibition caused by its exclusive clearance pathway via CYP3A4 oxidation in humans.","2-[(3aR,4R,5S,7aS)-5-{(1S)-1-[3,5-bis(trifluoromethyl)phenyl]-2-hydroxyethoxy}-4-(2-methylphenyl)octahydro-2H-isoindol-2-yl]-1,3-oxazol-4(5H)-one: a potent human NK1 receptor antagonist with multiple clearance pathways. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23808489/),h,40,59710,DB00673,Aprepitant
,25053387,K(i),The K(i) value was estimated to be 9.82 µM.,No pharmacokinetic alteration of docetaxel following coadministration of aprepitant 3 h before docetaxel infusion. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25053387/),μM,9.82,60435,DB00673,Aprepitant
,30607545,Cmax,Values for aprepitant group vs. control group were as follows: geometric mean of Cmax was 119 vs.,"Efficacy, Tolerability and Pharmacokinetic Impact of Aprepitant in Sarcoma Patients Receiving Ifosfamide and Doxorubicin Chemotherapy: A Randomized Controlled Trial. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30607545/),,119,64315,DB00673,Aprepitant
,30607545,AUC0-last,"120 ng/mL, AUC0-last was 648 vs.","Efficacy, Tolerability and Pharmacokinetic Impact of Aprepitant in Sarcoma Patients Receiving Ifosfamide and Doxorubicin Chemotherapy: A Randomized Controlled Trial. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30607545/),,648,64316,DB00673,Aprepitant
,30607545,AUC0-inf,"635 ng h/mL, AUC0-inf was 681 vs.","Efficacy, Tolerability and Pharmacokinetic Impact of Aprepitant in Sarcoma Patients Receiving Ifosfamide and Doxorubicin Chemotherapy: A Randomized Controlled Trial. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30607545/),,681,64317,DB00673,Aprepitant
,30607545,plasma clearance,"668 ng h/mL, plasma clearance was 4.40 vs.","Efficacy, Tolerability and Pharmacokinetic Impact of Aprepitant in Sarcoma Patients Receiving Ifosfamide and Doxorubicin Chemotherapy: A Randomized Controlled Trial. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30607545/),,4.40,64318,DB00673,Aprepitant
,30607545,t1/2,"4.49 (L/h/m2), respectively; harmonic means of t1/2 was 2.11 vs. 2.25 h.","Efficacy, Tolerability and Pharmacokinetic Impact of Aprepitant in Sarcoma Patients Receiving Ifosfamide and Doxorubicin Chemotherapy: A Randomized Controlled Trial. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30607545/),h,2.11,64319,DB00673,Aprepitant
,30607545,t1/2,"4.49 (L/h/m2), respectively; harmonic means of t1/2 was 2.11 vs. 2.25 h.","Efficacy, Tolerability and Pharmacokinetic Impact of Aprepitant in Sarcoma Patients Receiving Ifosfamide and Doxorubicin Chemotherapy: A Randomized Controlled Trial. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30607545/),h,2.25,64320,DB00673,Aprepitant
,29535504,area under the curve (AUC) from time 0 to time of last measurable plasma concentration (AUC0-t),"For HTX-019, mean (percent coefficient of variation) area under the curve (AUC) from time 0 to time of last measurable plasma concentration (AUC0-t), AUC from time 0 to infinity (AUC0-inf), and plasma concentration at 12 h (C12 h) for HTX-019 were 43,729 h*ng/mL (32.7), 45,460 h*ng/mL (36.8), and 988.4 ng/mL (27.5), respectively; corresponding fosaprepitant values were 44,130 h*ng/mL (32.0), 46,163 h*ng/mL (36.6), and 1,022 ng/mL (28.5).","Bioequivalence of HTX-019 (aprepitant IV) and fosaprepitant in healthy subjects: a Phase I, open-label, randomized, two-way crossover evaluation. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29535504/),[h·ng] / [ml],"43,729",67881,DB00673,Aprepitant
,29535504,AUC from time 0 to infinity (AUC0-inf),"For HTX-019, mean (percent coefficient of variation) area under the curve (AUC) from time 0 to time of last measurable plasma concentration (AUC0-t), AUC from time 0 to infinity (AUC0-inf), and plasma concentration at 12 h (C12 h) for HTX-019 were 43,729 h*ng/mL (32.7), 45,460 h*ng/mL (36.8), and 988.4 ng/mL (27.5), respectively; corresponding fosaprepitant values were 44,130 h*ng/mL (32.0), 46,163 h*ng/mL (36.6), and 1,022 ng/mL (28.5).","Bioequivalence of HTX-019 (aprepitant IV) and fosaprepitant in healthy subjects: a Phase I, open-label, randomized, two-way crossover evaluation. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29535504/),[h·ng] / [ml],"45,460",67882,DB00673,Aprepitant
,29535504,plasma concentration at 12 h (C12 h),"For HTX-019, mean (percent coefficient of variation) area under the curve (AUC) from time 0 to time of last measurable plasma concentration (AUC0-t), AUC from time 0 to infinity (AUC0-inf), and plasma concentration at 12 h (C12 h) for HTX-019 were 43,729 h*ng/mL (32.7), 45,460 h*ng/mL (36.8), and 988.4 ng/mL (27.5), respectively; corresponding fosaprepitant values were 44,130 h*ng/mL (32.0), 46,163 h*ng/mL (36.6), and 1,022 ng/mL (28.5).","Bioequivalence of HTX-019 (aprepitant IV) and fosaprepitant in healthy subjects: a Phase I, open-label, randomized, two-way crossover evaluation. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29535504/),[ng] / [ml],988.4,67883,DB00673,Aprepitant
,29535504,plasma concentration at 12 h (C12 h),"For HTX-019, mean (percent coefficient of variation) area under the curve (AUC) from time 0 to time of last measurable plasma concentration (AUC0-t), AUC from time 0 to infinity (AUC0-inf), and plasma concentration at 12 h (C12 h) for HTX-019 were 43,729 h*ng/mL (32.7), 45,460 h*ng/mL (36.8), and 988.4 ng/mL (27.5), respectively; corresponding fosaprepitant values were 44,130 h*ng/mL (32.0), 46,163 h*ng/mL (36.6), and 1,022 ng/mL (28.5).","Bioequivalence of HTX-019 (aprepitant IV) and fosaprepitant in healthy subjects: a Phase I, open-label, randomized, two-way crossover evaluation. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29535504/),[ng] / [ml],"1,022",67884,DB00673,Aprepitant
,23370406,120-h,The median and interquartile ranges of the 120-h area under the plasma concentration time curve (AUC)(0-120) of aprepitant were 73215 and 55518-91121 ng h/mL.,Interindividual variations in aprepitant plasma pharmacokinetics in cancer patients receiving cisplatin-based chemotherapy for the first time. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23370406/),[h·ng] / [ml],73215,98457,DB00673,Aprepitant
,23370406,area under the plasma concentration time curve (AUC)(0-120),The median and interquartile ranges of the 120-h area under the plasma concentration time curve (AUC)(0-120) of aprepitant were 73215 and 55518-91121 ng h/mL.,Interindividual variations in aprepitant plasma pharmacokinetics in cancer patients receiving cisplatin-based chemotherapy for the first time. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23370406/),[h·ng] / [ml],73215,98458,DB00673,Aprepitant
,23370406,area under the plasma concentration time curve (AUC)(0-120),The median and interquartile ranges of the 120-h area under the plasma concentration time curve (AUC)(0-120) of aprepitant were 73215 and 55518-91121 ng h/mL.,Interindividual variations in aprepitant plasma pharmacokinetics in cancer patients receiving cisplatin-based chemotherapy for the first time. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23370406/),[h·ng] / [ml],55518-91121,98459,DB00673,Aprepitant
,23240730,bioavailability,The innovator Emend® is a formulation incorporating drug nanoparticles with good bioavailability (~67%).,Inclusion complex of aprepitant with cyclodextrin: evaluation of physico-chemical and pharmacokinetic properties. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23240730/),%,67,152674,DB00673,Aprepitant
,22739139,occup,"Brain NK1R occupancy rates after i.v. fosaprepitant at time to peak concentration (T(max); ~30 min), 24, 48, and 120 h after the dose were 100, 100, ≥97, and 41-75%, respectively.",Equivalent dynamic human brain NK1-receptor occupancy following single-dose i.v. fosaprepitant vs. oral aprepitant as assessed by PET imaging. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22739139/),min,30,168972,DB00673,Aprepitant
,22739139,occup,"Brain NK1R occupancy rates after i.v. fosaprepitant at time to peak concentration (T(max); ~30 min), 24, 48, and 120 h after the dose were 100, 100, ≥97, and 41-75%, respectively.",Equivalent dynamic human brain NK1-receptor occupancy following single-dose i.v. fosaprepitant vs. oral aprepitant as assessed by PET imaging. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22739139/),%,100,168973,DB00673,Aprepitant
,22739139,time to peak concentration (T(max),"Brain NK1R occupancy rates after i.v. fosaprepitant at time to peak concentration (T(max); ~30 min), 24, 48, and 120 h after the dose were 100, 100, ≥97, and 41-75%, respectively.",Equivalent dynamic human brain NK1-receptor occupancy following single-dose i.v. fosaprepitant vs. oral aprepitant as assessed by PET imaging. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22739139/),min,30,168974,DB00673,Aprepitant
,22739139,time to peak concentration (T(max),"Brain NK1R occupancy rates after i.v. fosaprepitant at time to peak concentration (T(max); ~30 min), 24, 48, and 120 h after the dose were 100, 100, ≥97, and 41-75%, respectively.",Equivalent dynamic human brain NK1-receptor occupancy following single-dose i.v. fosaprepitant vs. oral aprepitant as assessed by PET imaging. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22739139/),%,24,168975,DB00673,Aprepitant
,22739139,time to peak concentration (T(max),"Brain NK1R occupancy rates after i.v. fosaprepitant at time to peak concentration (T(max); ~30 min), 24, 48, and 120 h after the dose were 100, 100, ≥97, and 41-75%, respectively.",Equivalent dynamic human brain NK1-receptor occupancy following single-dose i.v. fosaprepitant vs. oral aprepitant as assessed by PET imaging. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22739139/),%,48,168976,DB00673,Aprepitant
,22739139,time to peak concentration (T(max),"Brain NK1R occupancy rates after i.v. fosaprepitant at time to peak concentration (T(max); ~30 min), 24, 48, and 120 h after the dose were 100, 100, ≥97, and 41-75%, respectively.",Equivalent dynamic human brain NK1-receptor occupancy following single-dose i.v. fosaprepitant vs. oral aprepitant as assessed by PET imaging. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22739139/),%,120,168977,DB00673,Aprepitant
,22739139,time to peak concentration (T(max),"Brain NK1R occupancy rates after i.v. fosaprepitant at time to peak concentration (T(max); ~30 min), 24, 48, and 120 h after the dose were 100, 100, ≥97, and 41-75%, respectively.",Equivalent dynamic human brain NK1-receptor occupancy following single-dose i.v. fosaprepitant vs. oral aprepitant as assessed by PET imaging. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22739139/),%,100,168978,DB00673,Aprepitant
,22739139,time to peak concentration (T(max),"Brain NK1R occupancy rates after i.v. fosaprepitant at time to peak concentration (T(max); ~30 min), 24, 48, and 120 h after the dose were 100, 100, ≥97, and 41-75%, respectively.",Equivalent dynamic human brain NK1-receptor occupancy following single-dose i.v. fosaprepitant vs. oral aprepitant as assessed by PET imaging. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22739139/),%,≥,168979,DB00673,Aprepitant
,22739139,time to peak concentration (T(max),"Brain NK1R occupancy rates after i.v. fosaprepitant at time to peak concentration (T(max); ~30 min), 24, 48, and 120 h after the dose were 100, 100, ≥97, and 41-75%, respectively.",Equivalent dynamic human brain NK1-receptor occupancy following single-dose i.v. fosaprepitant vs. oral aprepitant as assessed by PET imaging. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22739139/),%,97,168980,DB00673,Aprepitant
,22739139,time to peak concentration (T(max),"Brain NK1R occupancy rates after i.v. fosaprepitant at time to peak concentration (T(max); ~30 min), 24, 48, and 120 h after the dose were 100, 100, ≥97, and 41-75%, respectively.",Equivalent dynamic human brain NK1-receptor occupancy following single-dose i.v. fosaprepitant vs. oral aprepitant as assessed by PET imaging. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22739139/),%,41-75,168981,DB00673,Aprepitant
,22739139,occupancy rates,"After aprepitant, NK1R occupancy rates at these time points (T(max) ~4 h) were ≥99, ≥99, ≥97, and 37-76%, respectively.",Equivalent dynamic human brain NK1-receptor occupancy following single-dose i.v. fosaprepitant vs. oral aprepitant as assessed by PET imaging. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22739139/),h,4,168982,DB00673,Aprepitant
≥,22739139,occupancy rates,"After aprepitant, NK1R occupancy rates at these time points (T(max) ~4 h) were ≥99, ≥99, ≥97, and 37-76%, respectively.",Equivalent dynamic human brain NK1-receptor occupancy following single-dose i.v. fosaprepitant vs. oral aprepitant as assessed by PET imaging. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22739139/),%,99,168983,DB00673,Aprepitant
,22739139,T(max),"After aprepitant, NK1R occupancy rates at these time points (T(max) ~4 h) were ≥99, ≥99, ≥97, and 37-76%, respectively.",Equivalent dynamic human brain NK1-receptor occupancy following single-dose i.v. fosaprepitant vs. oral aprepitant as assessed by PET imaging. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22739139/),h,4,168984,DB00673,Aprepitant
≥,22739139,T(max),"After aprepitant, NK1R occupancy rates at these time points (T(max) ~4 h) were ≥99, ≥99, ≥97, and 37-76%, respectively.",Equivalent dynamic human brain NK1-receptor occupancy following single-dose i.v. fosaprepitant vs. oral aprepitant as assessed by PET imaging. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22739139/),%,99,168985,DB00673,Aprepitant
≥,22739139,T(max),"After aprepitant, NK1R occupancy rates at these time points (T(max) ~4 h) were ≥99, ≥99, ≥97, and 37-76%, respectively.",Equivalent dynamic human brain NK1-receptor occupancy following single-dose i.v. fosaprepitant vs. oral aprepitant as assessed by PET imaging. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22739139/),%,97,168986,DB00673,Aprepitant
≥,22739139,T(max),"After aprepitant, NK1R occupancy rates at these time points (T(max) ~4 h) were ≥99, ≥99, ≥97, and 37-76%, respectively.",Equivalent dynamic human brain NK1-receptor occupancy following single-dose i.v. fosaprepitant vs. oral aprepitant as assessed by PET imaging. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22739139/),%,37-76,168987,DB00673,Aprepitant
,30680523,area under the docetaxel curve (AUC0-t,"In two groups, the area under the docetaxel curve (AUC0-t values) (mean ± SD) of docetaxel was 1134.21 ± 732.55 (ng h/mL) and 1080.94 ± 585.09 (ng h/mL), and the geometric means were 944.82 and 902.10 (ng h/mL), respectively.",Effect of aprepitant administration on CINV caused by cisplatin multi-day chemotherapy and pharmacokinetics of docetaxel. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30680523/),[h·ng] / [ml],1134.21,172861,DB00673,Aprepitant
,30680523,area under the docetaxel curve (AUC0-t,"In two groups, the area under the docetaxel curve (AUC0-t values) (mean ± SD) of docetaxel was 1134.21 ± 732.55 (ng h/mL) and 1080.94 ± 585.09 (ng h/mL), and the geometric means were 944.82 and 902.10 (ng h/mL), respectively.",Effect of aprepitant administration on CINV caused by cisplatin multi-day chemotherapy and pharmacokinetics of docetaxel. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30680523/),[h·ng] / [ml],1080.94,172862,DB00673,Aprepitant
,30680523,area under the docetaxel curve (AUC0-t,"In two groups, the area under the docetaxel curve (AUC0-t values) (mean ± SD) of docetaxel was 1134.21 ± 732.55 (ng h/mL) and 1080.94 ± 585.09 (ng h/mL), and the geometric means were 944.82 and 902.10 (ng h/mL), respectively.",Effect of aprepitant administration on CINV caused by cisplatin multi-day chemotherapy and pharmacokinetics of docetaxel. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30680523/),[h·ng] / [ml],944.82,172863,DB00673,Aprepitant
,30680523,area under the docetaxel curve (AUC0-t,"In two groups, the area under the docetaxel curve (AUC0-t values) (mean ± SD) of docetaxel was 1134.21 ± 732.55 (ng h/mL) and 1080.94 ± 585.09 (ng h/mL), and the geometric means were 944.82 and 902.10 (ng h/mL), respectively.",Effect of aprepitant administration on CINV caused by cisplatin multi-day chemotherapy and pharmacokinetics of docetaxel. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30680523/),[h·ng] / [ml],902.10,172864,DB00673,Aprepitant
,15899109,plasma elimination half-life,"With and without aprepitant coadministration, respectively, mean plasma elimination half-life was 40 hours and 43 hours (difference: -3.0 hours; p = 0.348), mean total body clearance was 130 mL/min and 136 mL/min (difference: -5.6 mL/min; p = 0.735), and mean volume of distribution at steady-state was 410.9 L and 442.3 L (difference: -31.4 L; p = 0.463).",Pharmacokinetics of palonosetron in combination with aprepitant in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15899109/),h,40,174671,DB00673,Aprepitant
,15899109,plasma elimination half-life,"With and without aprepitant coadministration, respectively, mean plasma elimination half-life was 40 hours and 43 hours (difference: -3.0 hours; p = 0.348), mean total body clearance was 130 mL/min and 136 mL/min (difference: -5.6 mL/min; p = 0.735), and mean volume of distribution at steady-state was 410.9 L and 442.3 L (difference: -31.4 L; p = 0.463).",Pharmacokinetics of palonosetron in combination with aprepitant in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15899109/),h,43,174672,DB00673,Aprepitant
,15899109,total body clearance,"With and without aprepitant coadministration, respectively, mean plasma elimination half-life was 40 hours and 43 hours (difference: -3.0 hours; p = 0.348), mean total body clearance was 130 mL/min and 136 mL/min (difference: -5.6 mL/min; p = 0.735), and mean volume of distribution at steady-state was 410.9 L and 442.3 L (difference: -31.4 L; p = 0.463).",Pharmacokinetics of palonosetron in combination with aprepitant in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15899109/),[ml] / [min],130,174673,DB00673,Aprepitant
,15899109,total body clearance,"With and without aprepitant coadministration, respectively, mean plasma elimination half-life was 40 hours and 43 hours (difference: -3.0 hours; p = 0.348), mean total body clearance was 130 mL/min and 136 mL/min (difference: -5.6 mL/min; p = 0.735), and mean volume of distribution at steady-state was 410.9 L and 442.3 L (difference: -31.4 L; p = 0.463).",Pharmacokinetics of palonosetron in combination with aprepitant in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15899109/),[ml] / [min],136,174674,DB00673,Aprepitant
,15899109,volume of distribution at steady-state,"With and without aprepitant coadministration, respectively, mean plasma elimination half-life was 40 hours and 43 hours (difference: -3.0 hours; p = 0.348), mean total body clearance was 130 mL/min and 136 mL/min (difference: -5.6 mL/min; p = 0.735), and mean volume of distribution at steady-state was 410.9 L and 442.3 L (difference: -31.4 L; p = 0.463).",Pharmacokinetics of palonosetron in combination with aprepitant in healthy volunteers. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15899109/),l,410.9,174675,DB00673,Aprepitant
,15899109,volume of distribution at steady-state,"With and without aprepitant coadministration, respectively, mean plasma elimination half-life was 40 hours and 43 hours (difference: -3.0 hours; p = 0.348), mean total body clearance was 130 mL/min and 136 mL/min (difference: -5.6 mL/min; p = 0.735), and mean volume of distribution at steady-state was 410.9 L and 442.3 L (difference: -31.4 L; p = 0.463).",Pharmacokinetics of palonosetron in combination with aprepitant in healthy volunteers. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15899109/),l,442.3,174676,DB00673,Aprepitant
,31694495,Relative bioavailability,Relative bioavailability of the aprepitant suspension was 82.3% (90% CI: 69.09-98.00%).,Relative bioavailability of an extemporaneously prepared aprepitant oral suspension in healthy adults. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31694495/),%,82.3,183003,DB00673,Aprepitant
,31694495,relative bioavailability,"With a relative bioavailability of 82.3%, the extemporaneous aprepitant oral suspension was well-absorbed relative to the capsule.",Relative bioavailability of an extemporaneously prepared aprepitant oral suspension in healthy adults. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31694495/),%,82.3,183004,DB00673,Aprepitant
,12756213,plasma clearance,"The slow plasma clearance of aprepitant ( approximately 1.5 ml/min/kg) and its abundance in ferret brain were in accord with its efficacy in blocking the retching and vomiting at 24 and 48 h postdose when ferrets were challenged with the emetic anticancer drug, cisplatin.","Brain penetration of aprepitant, a substance P receptor antagonist, in ferrets. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12756213/),[ml] / [kg·min],1.5,194479,DB00673,Aprepitant
,22245954,area under concentration-time curve (AUC(0-t),"The geometric mean area under concentration-time curve (AUC(0-t) μg/mL h) for cyclophosphamide was 282 following aprepitant and 230 following placebo (ratio 1.23; 90% CI 1.13, 1.33).",The effect of aprepitant and race on the pharmacokinetics of cyclophosphamide in breast cancer patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22245954/),[μg] / [h·ml],282,211078,DB00673,Aprepitant
,22245954,area under concentration-time curve (AUC(0-t),"The geometric mean area under concentration-time curve (AUC(0-t) μg/mL h) for cyclophosphamide was 282 following aprepitant and 230 following placebo (ratio 1.23; 90% CI 1.13, 1.33).",The effect of aprepitant and race on the pharmacokinetics of cyclophosphamide in breast cancer patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22245954/),[μg] / [h·ml],230,211079,DB00673,Aprepitant
,22245954,AUC(0-t),"DCE AUC(0-t) (μg/mL h) was 6.76 following aprepitant and 9.37 following placebo (ratio 0.72; 90% CI 0.64, 0.81).",The effect of aprepitant and race on the pharmacokinetics of cyclophosphamide in breast cancer patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22245954/),[μg] / [h·ml],6,211080,DB00673,Aprepitant
,22245954,AUC(0-t),"DCE AUC(0-t) (μg/mL h) was 6.76 following aprepitant and 9.37 following placebo (ratio 0.72; 90% CI 0.64, 0.81).",The effect of aprepitant and race on the pharmacokinetics of cyclophosphamide in breast cancer patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22245954/),[μg] / [h·ml],9,211081,DB00673,Aprepitant
,15723220,AUC(0-last),Values for docetaxel alone (treatment A) versus docetaxel with aprepitant (treatment B) were as follows: geometric mean AUC(0-last) was 3.26 vs 3.17 microg h/ml (P>0.25; ratio B/A 0.97); geometric mean AUC(0-infinity) 3.51 vs 3.39 microg h/ml (P>0.25; ratio B/A 0.96); geometric mean C(max) was 3.53 vs 3.37 microg/ml (P>0.25; ratio B/A 0.95); and geometric mean plasma clearance was 23.3 vs 24.2 l/h/m(2) (P>0.25; ratio B/A 1.04).,Lack of effect of aprepitant on the pharmacokinetics of docetaxel in cancer patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15723220/),[h·μg] / [ml],3.26,212820,DB00673,Aprepitant
,15723220,AUC(0-last),Values for docetaxel alone (treatment A) versus docetaxel with aprepitant (treatment B) were as follows: geometric mean AUC(0-last) was 3.26 vs 3.17 microg h/ml (P>0.25; ratio B/A 0.97); geometric mean AUC(0-infinity) 3.51 vs 3.39 microg h/ml (P>0.25; ratio B/A 0.96); geometric mean C(max) was 3.53 vs 3.37 microg/ml (P>0.25; ratio B/A 0.95); and geometric mean plasma clearance was 23.3 vs 24.2 l/h/m(2) (P>0.25; ratio B/A 1.04).,Lack of effect of aprepitant on the pharmacokinetics of docetaxel in cancer patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15723220/),[h·μg] / [ml],3.17,212821,DB00673,Aprepitant
,15723220,AUC(0-infinity),Values for docetaxel alone (treatment A) versus docetaxel with aprepitant (treatment B) were as follows: geometric mean AUC(0-last) was 3.26 vs 3.17 microg h/ml (P>0.25; ratio B/A 0.97); geometric mean AUC(0-infinity) 3.51 vs 3.39 microg h/ml (P>0.25; ratio B/A 0.96); geometric mean C(max) was 3.53 vs 3.37 microg/ml (P>0.25; ratio B/A 0.95); and geometric mean plasma clearance was 23.3 vs 24.2 l/h/m(2) (P>0.25; ratio B/A 1.04).,Lack of effect of aprepitant on the pharmacokinetics of docetaxel in cancer patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15723220/),[h·μg] / [ml],3.51,212822,DB00673,Aprepitant
,15723220,AUC(0-infinity),Values for docetaxel alone (treatment A) versus docetaxel with aprepitant (treatment B) were as follows: geometric mean AUC(0-last) was 3.26 vs 3.17 microg h/ml (P>0.25; ratio B/A 0.97); geometric mean AUC(0-infinity) 3.51 vs 3.39 microg h/ml (P>0.25; ratio B/A 0.96); geometric mean C(max) was 3.53 vs 3.37 microg/ml (P>0.25; ratio B/A 0.95); and geometric mean plasma clearance was 23.3 vs 24.2 l/h/m(2) (P>0.25; ratio B/A 1.04).,Lack of effect of aprepitant on the pharmacokinetics of docetaxel in cancer patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15723220/),[h·μg] / [ml],3.39,212823,DB00673,Aprepitant
,15723220,C(max),Values for docetaxel alone (treatment A) versus docetaxel with aprepitant (treatment B) were as follows: geometric mean AUC(0-last) was 3.26 vs 3.17 microg h/ml (P>0.25; ratio B/A 0.97); geometric mean AUC(0-infinity) 3.51 vs 3.39 microg h/ml (P>0.25; ratio B/A 0.96); geometric mean C(max) was 3.53 vs 3.37 microg/ml (P>0.25; ratio B/A 0.95); and geometric mean plasma clearance was 23.3 vs 24.2 l/h/m(2) (P>0.25; ratio B/A 1.04).,Lack of effect of aprepitant on the pharmacokinetics of docetaxel in cancer patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15723220/),[μg] / [ml],3.53,212824,DB00673,Aprepitant
,15723220,C(max),Values for docetaxel alone (treatment A) versus docetaxel with aprepitant (treatment B) were as follows: geometric mean AUC(0-last) was 3.26 vs 3.17 microg h/ml (P>0.25; ratio B/A 0.97); geometric mean AUC(0-infinity) 3.51 vs 3.39 microg h/ml (P>0.25; ratio B/A 0.96); geometric mean C(max) was 3.53 vs 3.37 microg/ml (P>0.25; ratio B/A 0.95); and geometric mean plasma clearance was 23.3 vs 24.2 l/h/m(2) (P>0.25; ratio B/A 1.04).,Lack of effect of aprepitant on the pharmacokinetics of docetaxel in cancer patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15723220/),[μg] / [ml],3.37,212825,DB00673,Aprepitant
,15723220,plasma clearance,Values for docetaxel alone (treatment A) versus docetaxel with aprepitant (treatment B) were as follows: geometric mean AUC(0-last) was 3.26 vs 3.17 microg h/ml (P>0.25; ratio B/A 0.97); geometric mean AUC(0-infinity) 3.51 vs 3.39 microg h/ml (P>0.25; ratio B/A 0.96); geometric mean C(max) was 3.53 vs 3.37 microg/ml (P>0.25; ratio B/A 0.95); and geometric mean plasma clearance was 23.3 vs 24.2 l/h/m(2) (P>0.25; ratio B/A 1.04).,Lack of effect of aprepitant on the pharmacokinetics of docetaxel in cancer patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15723220/),[h·l] / [m(2],23.3,212826,DB00673,Aprepitant
,15723220,plasma clearance,Values for docetaxel alone (treatment A) versus docetaxel with aprepitant (treatment B) were as follows: geometric mean AUC(0-last) was 3.26 vs 3.17 microg h/ml (P>0.25; ratio B/A 0.97); geometric mean AUC(0-infinity) 3.51 vs 3.39 microg h/ml (P>0.25; ratio B/A 0.96); geometric mean C(max) was 3.53 vs 3.37 microg/ml (P>0.25; ratio B/A 0.95); and geometric mean plasma clearance was 23.3 vs 24.2 l/h/m(2) (P>0.25; ratio B/A 1.04).,Lack of effect of aprepitant on the pharmacokinetics of docetaxel in cancer patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15723220/),[h·l] / [m(2],24.2,212827,DB00673,Aprepitant
,15723220,half-life,The corresponding harmonic mean half-life values were 10.1 and 8.5 h.,Lack of effect of aprepitant on the pharmacokinetics of docetaxel in cancer patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15723220/),h,10.1,212828,DB00673,Aprepitant
,15723220,half-life,The corresponding harmonic mean half-life values were 10.1 and 8.5 h.,Lack of effect of aprepitant on the pharmacokinetics of docetaxel in cancer patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15723220/),h,8.5,212829,DB00673,Aprepitant
,15723220,absolute neutrophil count nadirs,The two treatment regimens had similar tolerability profiles; the median absolute neutrophil count nadirs were 681/mm(3) during treatment with docetaxel alone and 975/mm(3) during aprepitant coadministration.,Lack of effect of aprepitant on the pharmacokinetics of docetaxel in cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15723220/),1/[mm(3],681,212830,DB00673,Aprepitant
,15723220,absolute neutrophil count nadirs,The two treatment regimens had similar tolerability profiles; the median absolute neutrophil count nadirs were 681/mm(3) during treatment with docetaxel alone and 975/mm(3) during aprepitant coadministration.,Lack of effect of aprepitant on the pharmacokinetics of docetaxel in cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15723220/),1/[mm(3],975,212831,DB00673,Aprepitant
,21931661,viral load,"Geometric mean baseline viral load (copies/ml) for Low, High, and PL was 15,709, 33,013, and 19,450, respectively.","A randomized, placebo controlled, double masked phase IB study evaluating the safety and antiviral activity of aprepitant, a neurokinin-1 receptor antagonist in HIV-1 infected adults. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21931661/),[copies] / [ml],"15,709",215695,DB00673,Aprepitant
,21931661,viral load,"Geometric mean baseline viral load (copies/ml) for Low, High, and PL was 15,709, 33,013, and 19,450, respectively.","A randomized, placebo controlled, double masked phase IB study evaluating the safety and antiviral activity of aprepitant, a neurokinin-1 receptor antagonist in HIV-1 infected adults. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21931661/),[copies] / [ml],"33,013",215696,DB00673,Aprepitant
,21931661,viral load,"Geometric mean baseline viral load (copies/ml) for Low, High, and PL was 15,709, 33,013, and 19,450, respectively.","A randomized, placebo controlled, double masked phase IB study evaluating the safety and antiviral activity of aprepitant, a neurokinin-1 receptor antagonist in HIV-1 infected adults. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21931661/),[copies] / [ml],"19,450",215697,DB00673,Aprepitant
,27718000,AUCinf,"Following coadministration of aprepitant with bosutinib, the area under the concentration-time curve from time zero extrapolated to infinity (AUCinf) and maximum plasma concentration (C max) were higher than in bosutinib alone (AUCinf, 4719 and 2268 ng•h/mL; C max, 146.0 and 94.94 ng/mL).","Effect of aprepitant, a moderate CYP3A4 inhibitor, on bosutinib exposure in healthy subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27718000/),[h·ng] / [ml],4719,222551,DB00673,Aprepitant
,27718000,AUCinf,"Following coadministration of aprepitant with bosutinib, the area under the concentration-time curve from time zero extrapolated to infinity (AUCinf) and maximum plasma concentration (C max) were higher than in bosutinib alone (AUCinf, 4719 and 2268 ng•h/mL; C max, 146.0 and 94.94 ng/mL).","Effect of aprepitant, a moderate CYP3A4 inhibitor, on bosutinib exposure in healthy subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27718000/),[h·ng] / [ml],2268,222552,DB00673,Aprepitant
,27718000,C max,"Following coadministration of aprepitant with bosutinib, the area under the concentration-time curve from time zero extrapolated to infinity (AUCinf) and maximum plasma concentration (C max) were higher than in bosutinib alone (AUCinf, 4719 and 2268 ng•h/mL; C max, 146.0 and 94.94 ng/mL).","Effect of aprepitant, a moderate CYP3A4 inhibitor, on bosutinib exposure in healthy subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27718000/),[ng] / [ml],146.0,222553,DB00673,Aprepitant
,27718000,C max,"Following coadministration of aprepitant with bosutinib, the area under the concentration-time curve from time zero extrapolated to infinity (AUCinf) and maximum plasma concentration (C max) were higher than in bosutinib alone (AUCinf, 4719 and 2268 ng•h/mL; C max, 146.0 and 94.94 ng/mL).","Effect of aprepitant, a moderate CYP3A4 inhibitor, on bosutinib exposure in healthy subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27718000/),[ng] / [ml],94.94,222554,DB00673,Aprepitant
,27718000,terminal elimination half-life,"For bosutinib with aprepitant versus bosutinib alone, mean terminal elimination half-life was similar (25.99 vs 27.79 h), time to C max was longer (6.02 vs 4.15 h), and apparent oral clearance (CL/F) was decreased (105.9 vs 220.4 L/h).","Effect of aprepitant, a moderate CYP3A4 inhibitor, on bosutinib exposure in healthy subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27718000/),h,25.99,222555,DB00673,Aprepitant
,27718000,terminal elimination half-life,"For bosutinib with aprepitant versus bosutinib alone, mean terminal elimination half-life was similar (25.99 vs 27.79 h), time to C max was longer (6.02 vs 4.15 h), and apparent oral clearance (CL/F) was decreased (105.9 vs 220.4 L/h).","Effect of aprepitant, a moderate CYP3A4 inhibitor, on bosutinib exposure in healthy subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27718000/),h,27.79,222556,DB00673,Aprepitant
,27718000,time to C max,"For bosutinib with aprepitant versus bosutinib alone, mean terminal elimination half-life was similar (25.99 vs 27.79 h), time to C max was longer (6.02 vs 4.15 h), and apparent oral clearance (CL/F) was decreased (105.9 vs 220.4 L/h).","Effect of aprepitant, a moderate CYP3A4 inhibitor, on bosutinib exposure in healthy subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27718000/),h,6.02,222557,DB00673,Aprepitant
,27718000,time to C max,"For bosutinib with aprepitant versus bosutinib alone, mean terminal elimination half-life was similar (25.99 vs 27.79 h), time to C max was longer (6.02 vs 4.15 h), and apparent oral clearance (CL/F) was decreased (105.9 vs 220.4 L/h).","Effect of aprepitant, a moderate CYP3A4 inhibitor, on bosutinib exposure in healthy subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27718000/),h,4.15,222558,DB00673,Aprepitant
,27718000,apparent oral clearance (CL/F),"For bosutinib with aprepitant versus bosutinib alone, mean terminal elimination half-life was similar (25.99 vs 27.79 h), time to C max was longer (6.02 vs 4.15 h), and apparent oral clearance (CL/F) was decreased (105.9 vs 220.4 L/h).","Effect of aprepitant, a moderate CYP3A4 inhibitor, on bosutinib exposure in healthy subjects. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27718000/),[l] / [h],105.9,222559,DB00673,Aprepitant
,27718000,apparent oral clearance (CL/F),"For bosutinib with aprepitant versus bosutinib alone, mean terminal elimination half-life was similar (25.99 vs 27.79 h), time to C max was longer (6.02 vs 4.15 h), and apparent oral clearance (CL/F) was decreased (105.9 vs 220.4 L/h).","Effect of aprepitant, a moderate CYP3A4 inhibitor, on bosutinib exposure in healthy subjects. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27718000/),[l] / [h],220.4,222560,DB00673,Aprepitant
,12891225,half-life,The midazolam half-life values increased from 1.7 hours (prestudy) to 3.3 hours on both day 1 and day 5.,Effects of aprepitant on cytochrome P450 3A4 activity using midazolam as a probe. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12891225/),h,1.7,245082,DB00673,Aprepitant
,12891225,half-life,The midazolam half-life values increased from 1.7 hours (prestudy) to 3.3 hours on both day 1 and day 5.,Effects of aprepitant on cytochrome P450 3A4 activity using midazolam as a probe. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12891225/),h,3.3,245083,DB00673,Aprepitant
,26592754,PDI,It was observed that SCFG-SEP (F2 formulation) showed lowest PDI (0.2445 ± 0.03) as well as smallest particle size (127 ± 5.8 nm).,Formulation optimization of aprepitant microemulsion-loaded silicated corn fiber gum particles for enhanced bioavailability. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26592754/),,0.2445,252472,DB00673,Aprepitant
,27717999,AUCinf,"Dabigatran EM monotherapy and concurrent administration of dabigatran EM with bosutinib resulted in similar values for concentration time curves from time zero extrapolated to infinity (AUCinf), but slightly lower maximum plasma concentration (C max) values (AUCinf, 1182 and 1186 ng·h/mL, respectively; C max, 129.8 and 114.1 ng/mL).","Effect of bosutinib on the absorption of dabigatran etexilate mesylate, a P-glycoprotein substrate, in healthy subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27717999/),[h·ng] / [ml],1182,260008,DB00673,Aprepitant
,27717999,AUCinf,"Dabigatran EM monotherapy and concurrent administration of dabigatran EM with bosutinib resulted in similar values for concentration time curves from time zero extrapolated to infinity (AUCinf), but slightly lower maximum plasma concentration (C max) values (AUCinf, 1182 and 1186 ng·h/mL, respectively; C max, 129.8 and 114.1 ng/mL).","Effect of bosutinib on the absorption of dabigatran etexilate mesylate, a P-glycoprotein substrate, in healthy subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27717999/),[h·ng] / [ml],1186,260009,DB00673,Aprepitant
,27717999,C max,"Dabigatran EM monotherapy and concurrent administration of dabigatran EM with bosutinib resulted in similar values for concentration time curves from time zero extrapolated to infinity (AUCinf), but slightly lower maximum plasma concentration (C max) values (AUCinf, 1182 and 1186 ng·h/mL, respectively; C max, 129.8 and 114.1 ng/mL).","Effect of bosutinib on the absorption of dabigatran etexilate mesylate, a P-glycoprotein substrate, in healthy subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27717999/),[ng] / [ml],129.8,260010,DB00673,Aprepitant
,27717999,C max,"Dabigatran EM monotherapy and concurrent administration of dabigatran EM with bosutinib resulted in similar values for concentration time curves from time zero extrapolated to infinity (AUCinf), but slightly lower maximum plasma concentration (C max) values (AUCinf, 1182 and 1186 ng·h/mL, respectively; C max, 129.8 and 114.1 ng/mL).","Effect of bosutinib on the absorption of dabigatran etexilate mesylate, a P-glycoprotein substrate, in healthy subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27717999/),[ng] / [ml],114.1,260011,DB00673,Aprepitant
,27717999,time to maximum concentration,The time to maximum concentration for dabigatran was 2.99 and 3.99 h for combination therapy.,"Effect of bosutinib on the absorption of dabigatran etexilate mesylate, a P-glycoprotein substrate, in healthy subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27717999/),h,2.99,260012,DB00673,Aprepitant
,27717999,time to maximum concentration,The time to maximum concentration for dabigatran was 2.99 and 3.99 h for combination therapy.,"Effect of bosutinib on the absorption of dabigatran etexilate mesylate, a P-glycoprotein substrate, in healthy subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27717999/),h,3.99,260013,DB00673,Aprepitant
,28978797,peak aprepitant plasma concentration,The mean peak aprepitant plasma concentration was 30.7 ± 15.3 μg/ml at day 14 and 23.3 ± 12.3 μg/ml at day 28.,Antiinflammatory effects of aprepitant coadministration with cART regimen containing ritonavir in HIV-infected adults. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28978797/),[μg] / [ml],30.7,264082,DB00673,Aprepitant
,28978797,peak aprepitant plasma concentration,The mean peak aprepitant plasma concentration was 30.7 ± 15.3 μg/ml at day 14 and 23.3 ± 12.3 μg/ml at day 28.,Antiinflammatory effects of aprepitant coadministration with cART regimen containing ritonavir in HIV-infected adults. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28978797/),[μg] / [ml],23.3,264083,DB00673,Aprepitant
,15336366,flow rate,"The analytes were chromatographed on a narrow bore (50 mm x 2.0 mm, 3 microm) Keystone Scientific's Prism R.P. analytical column, with mobile phase consisting of acetonitrile (ACN):water containing trifluoroacetic acid with pH adjusted to 3 (40:60, v/v) pumped at a flow rate of 0.5 ml/min.",Simultaneous determination of Aprepitant and two metabolites in human plasma by high-performance liquid chromatography with tandem mass spectrometric detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15336366/),[ml] / [min],0.5,264395,DB00673,Aprepitant
,12867217,AUC(0- infinity ),"Coadministration of aprepitant 375 mg produced a small but statistically significant increase in the AUC(0- infinity ) for intravenous ondansetron (from 1268.3 to 1456.5 ng.h/mL; P = 0.019), with no significant effect on peak concentration at the end of the infusion (360.8 ng/mL with aprepitant vs 408.4 ng/mL without) or t(12) (5.0 vs 4.5 hours, respectively).",Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12867217/),[h·ng] / [ml],1268.3,267183,DB00673,Aprepitant
,12867217,AUC(0- infinity ),"Coadministration of aprepitant 375 mg produced a small but statistically significant increase in the AUC(0- infinity ) for intravenous ondansetron (from 1268.3 to 1456.5 ng.h/mL; P = 0.019), with no significant effect on peak concentration at the end of the infusion (360.8 ng/mL with aprepitant vs 408.4 ng/mL without) or t(12) (5.0 vs 4.5 hours, respectively).",Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12867217/),[h·ng] / [ml],1456.5,267184,DB00673,Aprepitant
,12867217,peak concentration,"Coadministration of aprepitant 375 mg produced a small but statistically significant increase in the AUC(0- infinity ) for intravenous ondansetron (from 1268.3 to 1456.5 ng.h/mL; P = 0.019), with no significant effect on peak concentration at the end of the infusion (360.8 ng/mL with aprepitant vs 408.4 ng/mL without) or t(12) (5.0 vs 4.5 hours, respectively).",Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12867217/),[ng] / [ml],360.8,267185,DB00673,Aprepitant
,12867217,peak concentration,"Coadministration of aprepitant 375 mg produced a small but statistically significant increase in the AUC(0- infinity ) for intravenous ondansetron (from 1268.3 to 1456.5 ng.h/mL; P = 0.019), with no significant effect on peak concentration at the end of the infusion (360.8 ng/mL with aprepitant vs 408.4 ng/mL without) or t(12) (5.0 vs 4.5 hours, respectively).",Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12867217/),[ng] / [ml],408.4,267186,DB00673,Aprepitant
,12867217,t(12),"Coadministration of aprepitant 375 mg produced a small but statistically significant increase in the AUC(0- infinity ) for intravenous ondansetron (from 1268.3 to 1456.5 ng.h/mL; P = 0.019), with no significant effect on peak concentration at the end of the infusion (360.8 ng/mL with aprepitant vs 408.4 ng/mL without) or t(12) (5.0 vs 4.5 hours, respectively).",Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12867217/),h,5.0,267187,DB00673,Aprepitant
,12867217,t(12),"Coadministration of aprepitant 375 mg produced a small but statistically significant increase in the AUC(0- infinity ) for intravenous ondansetron (from 1268.3 to 1456.5 ng.h/mL; P = 0.019), with no significant effect on peak concentration at the end of the infusion (360.8 ng/mL with aprepitant vs 408.4 ng/mL without) or t(12) (5.0 vs 4.5 hours, respectively).",Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12867217/),h,4.5,267188,DB00673,Aprepitant
,12867217,AUC(0- infinity ),"Coadministration of aprepitant 125 mg/80 mg did not alter the mean pharmacokinetic characteristics of oral granisetron (AUC(0- infinity ), 101.4 ng.h/mL with aprepitant vs 92.2 ng.h/mL without; maximum plasma concentration, 9.0 ng/mL with and without aprepitant; time to maximum plasma concentration, both 3.0 hours; t(12), 6.5 vs 6.9 hours, respectively).",Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12867217/),[h·ng] / [ml],101.4,267189,DB00673,Aprepitant
,12867217,AUC(0- infinity ),"Coadministration of aprepitant 125 mg/80 mg did not alter the mean pharmacokinetic characteristics of oral granisetron (AUC(0- infinity ), 101.4 ng.h/mL with aprepitant vs 92.2 ng.h/mL without; maximum plasma concentration, 9.0 ng/mL with and without aprepitant; time to maximum plasma concentration, both 3.0 hours; t(12), 6.5 vs 6.9 hours, respectively).",Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12867217/),[h·ng] / [ml],92.2,267190,DB00673,Aprepitant
,12867217,maximum plasma concentration,"Coadministration of aprepitant 125 mg/80 mg did not alter the mean pharmacokinetic characteristics of oral granisetron (AUC(0- infinity ), 101.4 ng.h/mL with aprepitant vs 92.2 ng.h/mL without; maximum plasma concentration, 9.0 ng/mL with and without aprepitant; time to maximum plasma concentration, both 3.0 hours; t(12), 6.5 vs 6.9 hours, respectively).",Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12867217/),[ng] / [ml],9.0,267191,DB00673,Aprepitant
,12867217,time to maximum plasma concentration,"Coadministration of aprepitant 125 mg/80 mg did not alter the mean pharmacokinetic characteristics of oral granisetron (AUC(0- infinity ), 101.4 ng.h/mL with aprepitant vs 92.2 ng.h/mL without; maximum plasma concentration, 9.0 ng/mL with and without aprepitant; time to maximum plasma concentration, both 3.0 hours; t(12), 6.5 vs 6.9 hours, respectively).",Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12867217/),h,3.0,267192,DB00673,Aprepitant
,12867217,t(12),"Coadministration of aprepitant 125 mg/80 mg did not alter the mean pharmacokinetic characteristics of oral granisetron (AUC(0- infinity ), 101.4 ng.h/mL with aprepitant vs 92.2 ng.h/mL without; maximum plasma concentration, 9.0 ng/mL with and without aprepitant; time to maximum plasma concentration, both 3.0 hours; t(12), 6.5 vs 6.9 hours, respectively).",Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12867217/),h,6.5,267193,DB00673,Aprepitant
,12867217,t(12),"Coadministration of aprepitant 125 mg/80 mg did not alter the mean pharmacokinetic characteristics of oral granisetron (AUC(0- infinity ), 101.4 ng.h/mL with aprepitant vs 92.2 ng.h/mL without; maximum plasma concentration, 9.0 ng/mL with and without aprepitant; time to maximum plasma concentration, both 3.0 hours; t(12), 6.5 vs 6.9 hours, respectively).",Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12867217/),h,6.9,267194,DB00673,Aprepitant
,32273684,maximum plasma concentrations (Cmax),"Comparing the result of period 1 in Chinese and Caucasian subjects, the geometric least-squares mean maximum plasma concentrations (Cmax) were 1482 ng/mL and 1435 ng/mL, and the area under the concentration-time curve (AUC0-∞) 34,035 hr·ng/mL and 34,188 hr·ng/mL.",Comparison of Pharmacokinetics of Aprepitant in Healthy Chinese and Caucasian Subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32273684/),[ng] / [ml],1482,271873,DB00673,Aprepitant
,32273684,maximum plasma concentrations (Cmax),"Comparing the result of period 1 in Chinese and Caucasian subjects, the geometric least-squares mean maximum plasma concentrations (Cmax) were 1482 ng/mL and 1435 ng/mL, and the area under the concentration-time curve (AUC0-∞) 34,035 hr·ng/mL and 34,188 hr·ng/mL.",Comparison of Pharmacokinetics of Aprepitant in Healthy Chinese and Caucasian Subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32273684/),[ng] / [ml],1435,271874,DB00673,Aprepitant
,32273684,area under the concentration-time curve (AUC0-∞),"Comparing the result of period 1 in Chinese and Caucasian subjects, the geometric least-squares mean maximum plasma concentrations (Cmax) were 1482 ng/mL and 1435 ng/mL, and the area under the concentration-time curve (AUC0-∞) 34,035 hr·ng/mL and 34,188 hr·ng/mL.",Comparison of Pharmacokinetics of Aprepitant in Healthy Chinese and Caucasian Subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32273684/),[h·ng] / [ml],"34,035",271875,DB00673,Aprepitant
,32273684,area under the concentration-time curve (AUC0-∞),"Comparing the result of period 1 in Chinese and Caucasian subjects, the geometric least-squares mean maximum plasma concentrations (Cmax) were 1482 ng/mL and 1435 ng/mL, and the area under the concentration-time curve (AUC0-∞) 34,035 hr·ng/mL and 34,188 hr·ng/mL.",Comparison of Pharmacokinetics of Aprepitant in Healthy Chinese and Caucasian Subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32273684/),[h·ng] / [ml],"34,188",271876,DB00673,Aprepitant
,32273684,AUC0-24,"In period 2, the geometric mean AUC0-24 on Day 1 and Day 3 were 19,446 hr·ng/mL and 27,843 hr·ng/mL, and the geometric mean Cmax on Day 1 and Day 3 were 1423 ng/mL and 1757 ng/mL, respectively.",Comparison of Pharmacokinetics of Aprepitant in Healthy Chinese and Caucasian Subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32273684/),[h·ng] / [ml],"19,446",271877,DB00673,Aprepitant
,32273684,AUC0-24,"In period 2, the geometric mean AUC0-24 on Day 1 and Day 3 were 19,446 hr·ng/mL and 27,843 hr·ng/mL, and the geometric mean Cmax on Day 1 and Day 3 were 1423 ng/mL and 1757 ng/mL, respectively.",Comparison of Pharmacokinetics of Aprepitant in Healthy Chinese and Caucasian Subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32273684/),[h·ng] / [ml],"27,843",271878,DB00673,Aprepitant
,32273684,Cmax,"In period 2, the geometric mean AUC0-24 on Day 1 and Day 3 were 19,446 hr·ng/mL and 27,843 hr·ng/mL, and the geometric mean Cmax on Day 1 and Day 3 were 1423 ng/mL and 1757 ng/mL, respectively.",Comparison of Pharmacokinetics of Aprepitant in Healthy Chinese and Caucasian Subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32273684/),[ng] / [ml],1423,271879,DB00673,Aprepitant
,32273684,Cmax,"In period 2, the geometric mean AUC0-24 on Day 1 and Day 3 were 19,446 hr·ng/mL and 27,843 hr·ng/mL, and the geometric mean Cmax on Day 1 and Day 3 were 1423 ng/mL and 1757 ng/mL, respectively.",Comparison of Pharmacokinetics of Aprepitant in Healthy Chinese and Caucasian Subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32273684/),[ng] / [ml],1757,271880,DB00673,Aprepitant
,21175446,C(max),There were no differences observed for C(max) at the end of melphalan infusion (placebo 3431 ± 608 ng ml⁻¹ vs. aprepitant 3269 ± 660 ng ml⁻¹).,The NK₁ receptor antagonist aprepitant does not alter the pharmacokinetics of high-dose melphalan chemotherapy in patients with multiple myeloma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21175446/),ml⁻¹·ng,3431,271890,DB00673,Aprepitant
,21175446,C(max),There were no differences observed for C(max) at the end of melphalan infusion (placebo 3431 ± 608 ng ml⁻¹ vs. aprepitant 3269 ± 660 ng ml⁻¹).,The NK₁ receptor antagonist aprepitant does not alter the pharmacokinetics of high-dose melphalan chemotherapy in patients with multiple myeloma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21175446/),ml⁻¹·ng,3269,271891,DB00673,Aprepitant
,21175446,Total clearance,Total clearance of melphalan was 304 ± 58 ml min⁻¹ m⁻² (placebo) which was not influenced by aprepitant (288 ± 78 ml min⁻¹ m⁻²).,The NK₁ receptor antagonist aprepitant does not alter the pharmacokinetics of high-dose melphalan chemotherapy in patients with multiple myeloma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21175446/),min⁻¹·ml·m⁻²,304,271892,DB00673,Aprepitant
,21175446,Total clearance,Total clearance of melphalan was 304 ± 58 ml min⁻¹ m⁻² (placebo) which was not influenced by aprepitant (288 ± 78 ml min⁻¹ m⁻²).,The NK₁ receptor antagonist aprepitant does not alter the pharmacokinetics of high-dose melphalan chemotherapy in patients with multiple myeloma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21175446/),min⁻¹·ml·m⁻²,288,271893,DB00673,Aprepitant
,23053255,T (max),Twelve patients completed the study; T (max) occurred approximately 2 h after the initiation of the infusion.,Effect of aprepitant on the pharmacokinetics of the cyclin-dependent kinase inhibitor dinaciclib in patients with advanced malignancies. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23053255/),h,2,272846,DB00673,Aprepitant
